Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study-Reference-Cited by-同舟云学术

Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study

Published:2019-03-06 Issue:4 Volume:49 Page:347-353
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Vrdoljak J¹,Boban T²,Petrić Miše B²,Boraska Jelavić T²,Bajić Ž³,Tomić S⁴,Vrdoljak E²

Affiliation:

1. University of Split, Medical School, Šoltanska 2, 21000 Split, Croatia

2. Department of Oncology, Clinical Hospital Center Split, Spinčićeva 1, 21000 Split, Croatia

3. Scientific Unit, Psychiatric Hospital Sveti Ivan, Jankomir 11, 10000 Zagreb, Croatia

4. Department of Pathology, Forensic Medicine and Cytology, Clinical Hospital Split, Spinčićeva 1, 21000 Split, Croatia

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/49/4/347/28523640/hyz011.pdf

Reference31 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer;Aghajanian;Gynecol Oncol,2015

3. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial;Pujade-Lauraine;J Clin Oncol,2014

4. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N Eng J Med,2011

5. A phase 3 trial of bevacizumab in ovarian cancer;Perren;N Engl J Med,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A single institutional clinical outcome for stages III and IV ovarian cancer patients treated with dose‐dense TC therapy in the frontline or first platinum‐sensitive relapse setting;Journal of Obstetrics and Gynaecology Research;2024-07-02

2. Survival Outcomes of Epithelial Ovarian Cancer Patients Following Dose-dense Versus 3-Weekly Platinum–Paclitaxel Chemotherapy: A Meta-Analysis;Clinical Oncology;2023-02

3. A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial;Journal of Gynecologic Oncology;2021